Sparsha Pharma International
Hyderabad, India
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Sparsha Pharma International
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Hyderabad, India
- Modalities
- Transdermal patches (matrix, drug-in-adhesive, reservoir), Small molecule, Controlled substances (Fentanyl, Buprenorphine)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Sparsha Pharma International
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesTransdermal patches (matrix, drug-in-adhesive, reservoir), Small molecule, Controlled substances (Fentanyl, Buprenorphine)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Transdermal patches (matrix, drug-in-adhesive, reservoir), Small molecule, Controlled substances (Fentanyl, Buprenorphine)
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Manufacturing site information being gathered
Modalities: Transdermal patches (matrix, drug-in-adhesive, reservoir), Small molecule, Controlled substances (Fentanyl, Buprenorphine)
Capacity assessment: 55.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: